Citadel Advisors’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $232K | Buy |
+16,000
| New | +$186K | ﹤0.01% | 11094 |
|
|
2025
Q2 | – | Sell |
-1,200
| Closed | -$18K | – | 12407 |
|
|
2025
Q1 | $18K | Sell |
1,200
-600
| -33% | -$9.98K | ﹤0.01% | 13216 |
|
|
2024
Q4 | $29.6K | Buy |
1,800
+1,600
| +800% | +$31.6K | ﹤0.01% | 12888 |
|
|
2024
Q3 | $4.94K | Sell |
200
-2,500
| -93% | -$64.8K | ﹤0.01% | 13531 |
|
|
2024
Q2 | $68.4K | Sell |
2,700
-3,200
| -54% | -$82.9K | ﹤0.01% | 11403 |
|
|
2024
Q1 | $150K | Buy |
5,900
+3,200
| +119% | +$77.4K | ﹤0.01% | 10764 |
|
|
2023
Q4 | $61.2K | Buy |
2,700
+1,800
| +200% | +$37.2K | ﹤0.01% | 11569 |
|
|
2023
Q3 | $16.8K | Sell |
900
-36,500
| -98% | -$757K | ﹤0.01% | 12762 |
|
|
2023
Q2 | $972K | Sell |
37,400
-7,500
| -17% | -$201K | ﹤0.01% | 6514 |
|
|
2023
Q1 | $1.29M | Buy |
44,900
+3,600
| +9% | +$107K | ﹤0.01% | 6253 |
|
|
2022
Q4 | $1.22M | Sell |
41,300
-3,300
| -7% | -$93.9K | ﹤0.01% | 6429 |
|
|
2022
Q3 | $1.06M | Buy |
+44,600
| New | +$1.03M | ﹤0.01% | 6868 |
|
|
2021
Q3 | – | Sell |
-6,700
| Closed | -$290K | – | 13747 |
|
|
2021
Q2 | $290K | Buy |
+6,700
| New | +$285K | ﹤0.01% | 11348 |
|
|
2020
Q4 | – | Sell |
-6,200
| Closed | -$219K | – | 10866 |
|
|
2020
Q3 | $219K | Sell |
6,200
-3,000
| -33% | -$108K | ﹤0.01% | 8661 |
|
|
2020
Q2 | $347K | Sell |
9,200
-1,600
| -15% | -$52.7K | ﹤0.01% | 7679 |
|
|
2020
Q1 | $312K | Buy |
+10,800
| New | +$437K | ﹤0.01% | 7263 |
|
|
2019
Q4 | – | Sell |
-4,300
| Closed | -$236K | – | 9063 |
|
|
2019
Q3 | $236K | Sell |
4,300
-3,700
| -46% | -$190K | ﹤0.01% | 7925 |
|
|
2019
Q2 | $325K | Sell |
8,000
-14,000
| -64% | -$510K | ﹤0.01% | 7453 |
|
|
2019
Q1 | $665K | Buy |
22,000
+10,900
| +98% | +$373K | ﹤0.01% | 6303 |
|
|
2018
Q4 | $373K | Sell |
11,100
-12,900
| -54% | -$466K | ﹤0.01% | 6883 |
|
|
2018
Q3 | $1.01M | Buy |
24,000
+10,300
| +75% | +$407K | ﹤0.01% | 5524 |
|
|
2018
Q2 | $438K | Buy |
+13,700
| New | +$564K | ﹤0.01% | 6592 |
|
|
2018
Q1 | – | Sell |
-8,600
| Closed | -$464K | – | 8231 |
|
|
2017
Q4 | $464K | Buy |
8,600
+4,300
| +100% | +$238K | ﹤0.01% | 5766 |
|
|
2017
Q3 | $249K | Sell |
4,300
-6,000
| -58% | -$314K | ﹤0.01% | 6352 |
|
|
2017
Q2 | $508K | Buy |
+10,300
| New | +$474K | ﹤0.01% | 5083 |
|
|
2017
Q1 | – | Sell |
-4,400
| Closed | -$215K | – | 7394 |
|
|
2016
Q4 | $215K | Buy |
+4,400
| New | +$203K | ﹤0.01% | 6203 |
|
|
2016
Q2 | – | Sell |
-7,700
| Closed | -$344K | – | 6779 |
|
|
2016
Q1 | $344K | Buy |
7,700
+2,000
| +35% | +$81.1K | ﹤0.01% | 4908 |
|
|
2015
Q4 | $218K | Sell |
5,700
-3,200
| -36% | -$122K | ﹤0.01% | 5694 |
|
|
2015
Q3 | $283K | Sell |
8,900
-1,000
| -10% | -$34.9K | ﹤0.01% | 5656 |
|
|
2015
Q2 | $327K | Buy |
9,900
+2,300
| +30% | +$82K | ﹤0.01% | 5630 |
|
|
2015
Q1 | $313K | Sell |
7,600
-500
| -6% | -$20.2K | ﹤0.01% | 5590 |
|
|
2014
Q4 | $330K | Sell |
8,100
-800
| -9% | -$31.3K | ﹤0.01% | 5293 |
|
|
2014
Q3 | $326K | Sell |
8,900
-2,500
| -22% | -$108K | ﹤0.01% | 5160 |
|
|
2014
Q2 | $528K | Hold |
11,400
| – | – | ﹤0.01% | 4312 |
|
|
2014
Q1 | $469K | Buy |
11,400
+6,800
| +148% | +$253K | ﹤0.01% | 4429 |
|
|
2013
Q4 | $176K | Buy |
4,600
+2,300
| +100% | +$71K | ﹤0.01% | 5148 |
|
|
2013
Q3 | $55K | Buy |
+2,300
| New | +$51.6K | ﹤0.01% | 5733 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Citadel Advisors's ANIK Position: Q1 2026 in Review
Citadel Advisors increased its Anika Therapeutics (ANIK) stake by 11% in Q1 2026, buying an estimated $58K and bringing the position to 52,062 shares worth $755K. The position accounts for ﹤0.01% of the portfolio, ranked #8340.
Citadel Advisors first reported a position in ANIK in Q2 2013 and has held it in 47 quarters since. The position peaked at $7.05M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Citadel Advisors held 52,062 shares of Anika Therapeutics worth $755K as of Q1 2026.
- Citadel Advisors bought 4,996 Anika Therapeutics shares in Q1 2026, an estimated $58K.
- Anika Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8340 holding.
- Citadel Advisors first reported a position in Anika Therapeutics in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Anika Therapeutics position peaked at $7.05M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.